Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.


Options:
A: Arm Label: Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel | Arm Label: Arm B (Nab-Paclitaxel+Carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel, Drug: Pemetrexed | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Nab-Paclitaxel; Assigned to Arm(s): Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B (Nab-Paclitaxel+Carboplatin)
B: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Docetaxel 75 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel 75 mg/m^2
C: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Arm Label: Paclitaxel+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Gemcitabine+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine | Arm Label: Gemcitabine+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel+Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Gemcitabine+Carboplatin, Paclitaxel+Carboplatin, Pemetrexed+Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Paclitaxel+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine+Cisplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine+Carboplatin, Gemcitabine+Cisplatin
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: D